Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
Launched by MÄLARDALEN UNIVERSITY · Dec 2, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The RedSedCan Study is a clinical trial aimed at helping people with breast, colorectal, or prostate cancer reduce the amount of time they spend being inactive while undergoing treatment. Researchers believe that by encouraging patients to be more active, they can improve their overall well-being and reduce the risk of health problems in the future. This study will involve a digital program that patients can use to manage their activity levels during their cancer treatment, which includes therapies like chemotherapy and radiation.
To be part of this trial, participants need to be between the ages of 65 and 74 and have recently started or are planning to start treatment for breast, prostate, or colorectal cancer at hospitals in Uppsala and Västerås, Sweden. Unfortunately, individuals with severe mental health issues, significant vision problems, or those who cannot walk independently are not eligible. Those who join the study can expect to receive support and resources through this digital program to help them stay active during their treatment. This trial is currently not recruiting participants, but it aims to make a positive impact on the lives of cancer patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals diagnosed with breast, prostate, or colorectal cancer planned for or resently started neo- or adjuvant treatment (e.g. chemotherapy, radiotherapy, endocrine treatment) at the hospitals in Uppsala and Västerås, Sweden.
- Exclusion Criteria:
- • Individuals diagnosed with dementia.
- • Individuals diagnosed with severe psychiatric disease.
- • Individuals with severe loss of vision, or communicative ability.
- • Individuals who cannot walk independently indoors with or without a walking aid.
- • Individuals completed treatment for other cancer diseases less than 12 months ago or not recovered from previous cancer treatment.
About Mälardalen University
Mälardalen University is a leading academic institution in Sweden, renowned for its commitment to innovative research and development across various fields, including health sciences. As a clinical trial sponsor, the university leverages its multidisciplinary expertise to advance evidence-based practices and contribute to the understanding of complex health issues. Through collaboration with healthcare professionals and industry partners, Mälardalen University aims to enhance patient care and promote public health by facilitating high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Petra von Heideken Wågert, Professor
Principal Investigator
Mälardalen University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported